← All candidates
Five insider buys in the last year — $134.0K in all.
30 filings on record.
FEMYFEMASYS INC
NasdaqCM · Healthcare · $21.27M
$2.54
-0.78% · Sep 16
Five insider buys in the last year — $134.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 5 buys◆ 6 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what FEMY ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$21.27M
Float
7.3M
88% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
9.3
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Financial Officer
Elefant Dov
Bought $50.0K on Aug 7 — 15,625 sh @ $3.20, held direct, 100% of their stake.
No completed positions to measure
Chief Executive Officer
Lee-Sepsick Kathy
Bought $50.0K on Aug 7 — 15,625 sh @ $3.20, held direct, 100% of their stake.
No completed positions to measure
Chief Operating Officer
Canning John Charles
Bought $14.0K on Aug 7 — 4,375 sh @ $3.20, held direct, 100% of their stake.
First Form 4 on file
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
3 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
6 more transactions on Pro →Context
Wall St
$63.33 avg target
+2393.4% vs today
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q1 '26−$1.46 act+$0.34
Q4 '25−$0.20 act+$1.60
Q3 '25−$2.00 act+$0.60
Q2 '25−$3.20 act+$0.40
Coverage
Femasys Secures FDA Pathway for Non-Surgical ContraceptiveBenzinga · 4w agoFEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside PotentialStocktwits · 4w agoFemasys Secures FDA Approval for Modular PMA Pathway for FemBlocInvestorsHub · 4w agoFemasys partners with Medical Electronic Systems for FemSperm kitTipRanks · 09-23
The file stays open
30 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice